Janus kinase inhibitor gets PBS listing for eczema
Dermatologists will have another subsidised option for patients battling to control flares with topical therapy
The Janus kinase inhibitor upadacitinib will soon be available on the PBS for severe atopic dermatitis in teenagers and adults who fail to respond to active topical treatments.
From 1 February, an estimated 3600 Australians each year will benefit from the new listing for the oral medication, which is currently only indicated for rheumatoid arthritis, the Federal Government has announced.
